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Abstract
Background: Recent epidemiological and experimental data suggest a negative influence of shortened or disturbed night
sleep on glucose tolerance. Due to the high prevalence of sleep disorders this might be a major health issue. However, no
comparative studies of carbohydrate metabolism have been conducted in clinical sleep disorders.
Methodology/Principal Findings: We performed oral glucose tolerance tests (OGTT) and assessed additional parameters of
carbohydrate metabolism in patients suffering from obstructive sleep apnea syndrome (OSAS, N=25), restless legs
syndrome (RLS, N=18) or primary insomnia (N=21), and in healthy controls (N=33). Compared to controls, increased rates
of impaired glucose tolerance were found in OSAS (OR: 4.9) and RLS (OR: 4.7) patients, but not in primary insomnia patients
(OR: 1.6). In addition, HbA1c values were significantly increased in the same two patient groups. Significant positive
correlations were found between 2-h plasma glucose values measured during the OGTT and the apnea-arousal-index in
OSAS (r=0.56; p,0.05) and the periodic leg movement-arousal-index in RLS (r=0.56, p,0.05), respectively. Sleep duration
and other quantitative aspects of sleep were similar between patient groups.
Conclusions/Significance: Our findings suggest that some, but not all sleep disorders considerably compromise glucose
metabolism. Repeated arousals during sleep might be a pivotal causative factor deserving further experimental
investigations to reveal potential novel targets for the prevention of metabolic diseases.
Citation: Keckeis M, Lattova Z, Maurovich-Horvat E, Beitinger PA, Birkmann S, et al. (2010) Impaired Glucose Tolerance in Sleep Disorders. PLoS ONE 5(3): e9444.
doi:10.1371/journal.pone.0009444
Editor: David Finkelstein, The Mental Health Research Institute of Victoria, Australia
Received October 20, 2009; Accepted February 7, 2010; Published March 1, 2010
Copyright:  2010 Keckeis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the European Union Framework 6 (MCRTN-CT-2004-512362). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: thomas.pollmaecher@klinikum-ingolstadt.de
Introduction
Obesity and diabetes are closely linked medical conditions,
which, to a great extent, account for long-term morbidity and
mortality worldwide [1,2]. According to recent epidemiological
evidence, both obesity and diabetes are related to chronic short
sleep duration [3]. In healthy people even short-term sleep
restriction or experimentally induced disturbed sleep have been
shown to impair glucose tolerance [4,5] indicating that sleep might
be pivotal for metabolic homeostasis. However, very little is known
about metabolic alterations in defined sleep disorders.
Tentative evidence suggests that the obstructive sleep apnea
syndrome (OSAS) might be a risk factor for diabetes regardless of
concomitant obesity [6]. However, in OSAS it cannot be
determined whether impaired glucose tolerance is due to repeated
nocturnal oxygen desaturation or due to disturbed sleep per se. In
narcolepsy, increased incidence of diabetes is a long-standing
finding [7], but here obesity as a confounding variable has not
been ruled out [8]. Obesity has also been reported to be associated
to the restless legs syndrome [9] and a relationship between RLS,
diabetes [10] and impaired glucose tolerance [11] has been
reported. In contrast, no studies are available on body weight or
diabetes in primary insomnia. Hence, it would be of particular
importance to gather more information on metabolic alterations in
different sleep disorders.
To this end, we compared aspects of carbohydrate metabolism
between healthy controls and patients suffering from OSAS,
primary insomnia, or the restless legs syndrome (RLS). Insomnia
and RLS are both highly prevalent (.5% in the general
population [12,13]) yet clearly distinct conditions of chronically
disturbed sleep. Whereas primary insomnia is characterized by
prominent subjective difficulties in initiating and maintaining sleep
with only minor changes in objectively recorded sleep parameters
[14], RLS is characterized by an impairment of sleep onset due to
unpleasant feelings and an urge to move the limbs. In addition,
periodic limb movements in sleep (PLMS) are typical of RLS and
compromise sleep continuity to a similar extent as repeated apneic
events in OSAS [15].
Methods
Participants
The study protocol was approved by the ethics committee of the
Bavarian Medical Council, Munich, Germany. All subjects
provided written informed consent prior to entering the study.
Of 97 subjects investigated, 25 suffered from OSAS, 21 from
primary insomnia, 18 from RLS and 33 were healthy controls.
Subjects were recruited through advertisements in local newspa-
pers. All subjects had normal findings on medical examination;
they did not suffer from any psychiatric disorder and had a regular
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during 8 days of wrist actigrapy were excluded. Pregnant women,
shift workers, and persons who had travelled across multiple time
zones within 3 months prior to the study were excluded. Similarly,
subjects exhibiting other sleep disorders or known metabolic
disorders including diabetes were excluded. All subjects showed
normal results in numerous blood tests including a complete
haemogram, prothrombin clotting time, activated partial throm-
boplastin time, fibrinogen, aspartate aminotransferase (AST/
GOT) and alanine aminotransferase (ALT/GPT), LDH, lipase,
cholesterol, HDL-cholesterol, LDL-cholesterol, albumin, transfer-
rin, ferritin, iron, CRP, TSH, T3, T4, and cortisol levels,
potassium, sodium, calcium, chloride, magnesium, phosphate,
and urine drug monitoring. All subjects showed normal EEG
findings during waking.
RLS patients met the diagnostic criteria defined by the
International Restless Legs Syndrome Study Group [16] and did
not suffer from any severe somatic condition such as polyneurop-
athy or secondary RLS. The severity of RLS was assessed using
the International Restless Legs Syndrome Study Group Rating
Scale (IRLS) [17]. In patients suffering from primary insomnia as
well as in patients suffering from OSAS, diagnosis was based on
the International Classification of Sleep Disorders [18]. OSAS
patients with an apnea-hypopnea-index (AHI) above 15 (moderate
sleep apnea) were included. Controls did not suffer from any sleep
disturbances, and sleep related breathing disorder (AHI .5) was
excluded by an ambulatory sleep apnea screening (Weinmann
Somnocheck, Hamburg, Germany).
Procedure and Measurements
Subjects underwent a detailed check-up including a physical
examination, anthropometric measurements, a survey of sleep
history, waking EEG recordings, and a detailed medical and
psychiatric interview. In addition, sleep quality was evaluated by
means of the Pittsburgh Sleep Quality Index (PSQI) [19] and
daytime sleepiness using the Epworth Sleepiness Scale (ESS) [20].
To verify regular sleep-wake patterns participants were asked to
wear a wrist activity monitor (Cambridge Neurotechnology,
Cambridge, UK; Actiwatch Activity Analysis, Version 5.06) for
8 days prior to the study. In all patients standard nocturnal
polysomnography (PSG) was conducted for two nights. Poly-
somnographic (PSG) recordings were performed from 23:00 to
06:00 h including monitoring of the EEG (C4-A1 and C3-A2),
electrooculogram, submental electromyogram (EMG), the right
and left anterior tibialis surface EMG, electrocardiogram (EKG),
thoracic and abdominal movements, nasal airflow, finger oxim-
etry, and video monitoring. Sleep stages were scored according to
Rechtschaffen and Kales [21]. Sleep stages 3 and 4 were summed
up to slow-wave sleep (SWS). Arousals [22], PLMS [23], and
apneas/hypopneas were scored and the number of both PLMS
and apneas/hypopneas per hour of total sleep time (PLMS-index
and AHI, respectively) calculated. Additionally, we calculated the
number of both PLMS and apneas/hypopneas associated with
arousals (PLMS-arousal-index and apnea-arousal-index, respec-
tively). Sleep stages and associated parameters were scored by two
experienced scorers in each individual.
After the first night in the sleep laboratory subjects underwent a
4-hour oral glucose tolerance test (OGTT). All OGTTs were
performed at 08:00 a.m. after an overnight fast. Fasting samples to
assess glucose, insulin, and HbA1c were taken at baseline. After an
oral standard load of 75 g glucose, blood samples were taken at 30,
60, 120, 180 and 240 min. Glucose was immediately measured
using the glucose oxidase method (Synchrone DXC 800 1+2,
Beckmann Coulter, USA) with an inter-assay coefficient of
variation (CV) of 1.0–2.2% (DXC1) and 1.4–2.2% (DXC2).
Insulin samples were measured by using an ELISA (BioSource,
Germany) with an inter-assay CV of 4.2%. HbA1c measurement
was based on the assessment of total Hb using the colorimetric
method, the A1c concentration was determined by means of the
turbidimetric immuno-inhibition method (Synchrone DXC 800 1,
Beckmann Coulter, USA) with a inter-assay CV of 2.9–3.2%.
Standardized to the NGSP reference range was set at 4.3–5.8%.
According to the diagnostic criteria of the American Diabetes
Association [24] we defined normal glucose tolerance (NGT) as 2-
hour plasma glucose (2h-PG) concentrations (2 h after an oral
glucose challenge) ,140 mg/dl; impaired glucose tolerance was
defined as 2h-PG values $140 and diabetes as 2h-PG $200 mg/
dl. The total areas under the curve for glucose (AUCg) and insulin
(AUCi) were calculated using the linear trapezoidal rule [25]. The
combination of elevated HbA1c values (.5.5%) and impaired
fasting glucose values (FPG .100 mg/dl) was assessed as an
additional risk factor for the development of type 2 diabetes, since
several studies have shown that the combination of these
parameters is a stronger predictor for the risk of developing type
2 diabetes than increased fasting glucose alone [26–29]. Insulin
resistance was assessed using the homeostasis model assessment
(HOMA-IR) originally described by Mathew et al. [30] HOMA-
Table 2. Frequency of Patients with Normal Glucose
Tolerance or Impaired Glucose Tolerance.
Total
Normal glucose
tolerance
Impaired glucose
tolerance
Odds
ratio
N N (%) N (%)
OSAS 25 15 (60) 10 (40) 4.9
RLS 18 11 (61) 7 (39) 4.7
INS 17 14 (82) 3 (18) 1.6
CON 32 28 (88) 4 (12)
Normal Glucose Tolerance: 2h-PG#140 mg/dl; Impaired Glucose Tolerance: 2h-
PG$140 mg/dl.
OSAS, Obstructive sleep apnea syndrome; RLS, Restless legs syndrome; INS,
Insomnia; CON, controls.
x
2 (3)=7.95, p,0.05.
doi:10.1371/journal.pone.0009444.t002
Table 1. Baseline Characteristics of Study Participants.
OSAS RLS INS CON P-value
Females/
Males
0/25 { = 11/7 12/9 17/16 ,0.001
Age (years) 52.3 (10.8) 52.2 (13.0) 49.1 (9.7) 46.8 (7.7) .0.05
BMI (kg/m
2) 32.9 (5.4) { 25.4 (3.7) 25.0 (4.8) 24.7 (3.5) ,0.001
PSQI 6.7 (2.8) { = 9.3 (4.5) {
+ 13.1 (3.7) { 3.0 (2.0) ,0.001
ESS 11.2 (5.6) { % 7.9 (4.3) 6.4 (4.0) 6.8 (2.8) ,0.001
Data are mean (SD). Statistical comparison was done using Gabriel- or Games-
Howell-corrected oneway ANOVA.
OSAS, Obstructive sleep apnea syndrome; RLS, Restless legs syndrome; INS,
Insomnia; CON, controls; BMI, Body mass index; PSQI, Pittsburgh Sleep Quality
Index; ESS, Epworth Sleepiness Scale.
*p ,0.05, { p,0.01, { p,0.001, vs controls.
+ p,0.05, % p,0.01, = p,0.001, between groups.
OSAS: x
2 (1)=18.21, p,0.001; RLS: x
2 (1)=0.433, p.0.05; INS: x
2 (1)=0.163,
p.0.05, vs controls.
doi:10.1371/journal.pone.0009444.t001
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dl 6 mU/ml)=FPG mg/dl 6 FPI mU/ml/405. To encompass
both hepatic and peripheral insulin sensitivity we calculated a
composite measure of whole body insulin sensitivity (ISIcomposite)
recommended by Matsuda et al. [31] (ISIcomposite was calculated
using the following formula: ISIcomposite=10 000/! ((FPG 6
FPI) 6(mean OGTT glucose 6mean OGTT insulin)).
Statistical Analysis
Statistical analysis was performed using SPSS for Windows 16.0
(SPSS Inc., Chicago, Illinois). Using Gabriel- or Games-Howell-
corrected analysis of variance (ANOVA) tests we compared the
mean values of the basic characteristics age, BMI, PSQI and ESS
among the four groups. Because of their skewed distribution,
HbA1c, FPG, 2h-PG, fasting plasma insulin (FPI), the area under
the curve for glucose (AUCg) and the area under the curve for
insulin (AUCi) were z-transformed. On metabolic parameters
analysis of covariance (ANCOVA) was conducted with the BMI as
covariate.
A chi-square test was performed to compare the incidence of
IGT and/or combined elevated HbA1c and FPG values between
groups. After constructing 262 contingency tables odds ratios
(OR) were calculated. First-order partial correlation and bivariate
correlation, respectively, were done to determine the association
between continuous variables. P,0.05 was considered as statisti-
cally significant.
Table 3. Metabolic Parameters.
OSAS RLS INS CON
BMI-adjusted
P-value
HbA1c (%) 5.6 (0.4) { 5.5 (0.3) { 5.3 (0.3) 5.2 (0.3) ,0.01
FPG (mg/dl) 110.9 (15.6) 100.4 (10.1) 98.8 (8.9) 96.0 (8.0) .0.05
FPI (ml/ml) 16.2 (10.5) 8.7 (3.2) 10.3 (5.4) 8.9 (3.3) .0.05
2h-PG (mg/dl) 139.0 (55.7) 121.1 (40.8) 120.2 (17.8) 109.5 (23.k5) .0.05
2h-PI (ml/ml) 82.5 (67.3) 60.0 (67.8) 50.6 (21.3) 36.8 (29.2) .0.05
AUCg (mg/dl) 31882 (7592) 28063 (5748) 28369 (3500) 25859 (4014) .0.05
AUCi (ml/ml) 15024 (9396) 9873 (6921) 8437 (3588) 8307 (5258) .0.05
HOMA1-IR 4.7 (3.8) 2.2 (1.0) 2.5 (1.3) 2.1 (0.9) .0.05
ISIcomposite 3.1 (1.6) 6.3 (5.4) 5.1 (1.5) 5.5 (1.9) .0.05
Data are mean (SD). Statistical comparison was done using ANCOVA.
OSAS, Obstructive sleep apnea syndrome; RLS, Restless legs syndrome; INS, Insomnia; CON, controls; FPG=Fasting plasma glucose; FPI=Fasting plasma insulin; 2h-
PG=2h-Postload glucose; 2h-PI=2h-Postload insulin; AUCg=Area under the curve for glucose; HOMA1-IR=Homeostasis model assessment-1 of insulin resistance;
ISIcomposite=Insulin sensitivity index composite.
*p ,0.05, { p,0.01, { p,0.001.
doi:10.1371/journal.pone.0009444.t003
Table 4. Frequency of Patients with Normal or Elevated
HbA1c ($5.5%) & FPG ($100mg/dl).
Total
Normal
HbA1c&FPG
Elevated
HbA1c&FPG Odds ratio
N N (%) N (%)
OSAS 25 11 (44) 14(56) 20.0
RLS 17 11 (65) 6 (35) 8.5
INS 19 18 (95) 1 (5) 0.8
CON 33 31 (94) 2 (6)
OSAS, Obstructive sleep apnea syndrome; RLS, Restless legs syndrome; INS,
Insomnia; CON, controls; FPG=Fasting plasma glucose.
x
2 (3)=25?31, p,0?001.
doi:10.1371/journal.pone.0009444.t004
Table 5. Sleep Parameters.
OSAS RLS INS P-value
TIB (min) 437.5 (33.1) 449.2 (32.8) 435.7 (25.8) .0.05
TST (min) 339.0 (58.7) 345.9 (69.5) 337.3 (55.6) .0.05
SEI (%) 77.5 (11.8) 77.1 (14.6) 77.2 (10.8) .0.05
WASO (min) 75.7 (42.8) 75.3 50.1) 61.0 (35.6) .0.05
REM (min) 41.4 (18.5) { 73.0 (24.1) 70.8 (27.2) ,0.001
S1 (min) 92.2 (40.2) { 41.8 (20.0) 31.3 (14.5) ,0.001
S2 (min) 198.0 (47.9) 204.2 (47.9) 214.9 (39.5) .0.05
SWS (min) 7.4 (9.5) { 26.9 (29.1) 20.4 (17.5) ,0.01
SO (min) 21.2 (20.9) 22.3 (33.2) 22.4 (19.6) .0.05
SLREM (min) 137.7 (68.4) * 97.5 (72.8) 86.4 (46.9) ,0.05
SLSWS (min) 122.8 (104.9) * 67.9 (92.6) 37.3 (26.0) ,0.05
AHI 55.7 (27.1) { 3.3 (3.7) 1.6 (1.6) ,0.001
ODI 43.6 (29.7) { 1.9 (3.0) 1.4 (1.6) ,0.001
PLMS-Index 19.2 (20.4) 32.5 (33.1) 5.2 (7.2) { ,0.01
PLMS-arousal-index 12.8 (14.0) 14.8 (15.3) 2.8 (4.7) { ,0.01
Apnea-arousal-index 33.8 (25.6) { 0.8 (1.8) 0.3 (0.5) ,0.001
Data are mean (SD). Mean comparison was done using Gabriel- or Games-
Howell-corrected oneway ANOVA.
OSAS, Obstructive sleep apnea syndrome; RLS, Restless legs syndrome; INS,
Insomnia; CON, controls; TIB, Time in bed; TST, Total sleep time; SEI, Sleep
efficiency; WASO, Wake time after sleep onset; REM, Rapid eye movement sleep;
S1, Stage 1 sleep; S2, Stage 2 sleep, SWS, Slow wave sleep; SO, Sleep onset
latency; SLREM, REM sleep latency; SLSWS, SWS sleep latency; AHI, Apnea-
hypopnea-index; ODI, Oxygen-desaturation-index; PLMS-Index, Periodic leg
movements per hour of sleep; PLMS-arousal-index, PLMS associated with
arousals per hour of sleep; Apnea-arousal-index, Apneas and/or hypopneas
associated with arousals per hour.
*p ,0?05, { p,0?01, { p,0?001.
doi:10.1371/journal.pone.0009444.t005
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Table 1 shows the baseline characteristics for all subjects.
Groups did not differ with respect to age. As expected, OSAS
patients had a strongly increased BMI, whereas the BMI of RLS
and insomnia patients did not differ from controls. RLS patients
suffered from a severe restless legs syndrome (IRLS, 22.965.4).
OSAS patients were all males, yielding a statistically significant
gender difference between groups. RLS and primary insomnia
patients, however, did not show gender distributions different from
controls.
OGTT data indicated that no control and no primary insomnia
patient, but four OSAS patients and one RLS patient suffered
from diabetes. As shown in Table 2, 12% of the controls showed
2h-PG values indicating an impaired glucose tolerance. This rate
was significantly increased in OSAS (40%, OR 4.9) and RLS
(39%, OR 4.7) patients, but not in primary insomnia (18%, OR
1.6) patients. The rate of impaired glucose tolerance within groups
was not gender dependent (data not shown). As shown in Table 3,
mean HbA1c values were in the normal range (below 5.8%), but
differed significantly between groups after adjustment for the BMI.
A Sidak-corrected post-hoc test based on estimated marginal
means revealed that OSAS as well as RLS patients had
significantly higher HbA1c values than healthy controls. In both
OSAS and RLS patients the rate of patients displaying elevated
HbA1c and FPG was significantly increased. Accordingly, 56% of
the OSAS (OR 20.0) and 35% of the RLS (OR 8.5) patients
belonged to the high risk group for developing type 2 diabetes. In
contrast, only 5% of the insomniacs (OR 0.82) and 6% of the
controls showed elevated HbA1c plus FPG levels (see Table 4).
Daytime sleepiness (ESS) was highest in OSAS patients and did
not differ in the other patient groups from controls. In contrast,
night sleep was subjectively impaired in all three patient groups
compared to controls as assessed by the PSQI, and insomniacs
rated their sleep significantly worse than did OSAS and RLS
patients (Table 1). Patient groups did not differ significantly in the
total amount and efficiency of polysomnographically defined sleep.
Similarly, the amount of wakefulness during the night was
comparable between groups. OSAS patients showed less SWS
and REM sleep, but more stage 1 sleep than both other patients
groups. Due to the selection criteria of the present study, only
OSAS patients showed pathological apnea-hypopnea and oxygen
desaturation indices. Mean PLMS arousal indices were in the
pathological range in OSAS and RLS patients, but not in
insomnia patients (Table 5).
Tasali et al. [5] have shown that SWS suppression induced by
acoustic stimulation triggering repetitive microarousals leads to a
decrease in insulin sensitivity. Because OSAS and RLS are
characterized by repeated arousals due to apneas and PLMS, we
assessed whether they were related to those metabolic parameters
differing between patient groups. 2h-PG values correlated positively
Figure 1. Association between 2 hour-plasma glucose and the
apnea-arousal-index in obstructive sleep apnea patients. Partial
correlation coefficient (corrected for the BMI); r=0.56, p,0.05.
doi:10.1371/journal.pone.0009444.g001
Figure 2. Association between 2 hour-plasma glucose and the
oxygen-desaturation-index in obstructive sleep apnea pa-
tients. Partial correlation coefficient (corrected for the BMI); r=0.59,
p,0.05.
doi:10.1371/journal.pone.0009444.g002
Figure 3. Association between the 2 hour-plasma glucose and
the PLMS-arousal-index in restless legs patients. Pearson’s
correlation coefficient; r=0.56, p,0.05.
doi:10.1371/journal.pone.0009444.g003
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(r=0.59, p,0.05) in OSAS, and with the PLMS-arousal-index
(r=0.56, p,0.05) in RLS (Figures 1–3). HbA1c correlated
positively with the apnea-arousal-index (r=0.50, p,0.05) in OSAS,
which was neither the case for the ODI (r=0.46, p.0.05), nor for
the PLMS-arousal-index (r=0.21, p.0.05) in RLS.
Discussion
The present study for the first time compared glucose
metabolism in various sleep disorders. The major finding is an
increased rate of impaired glucose tolerance in patients with
OSAS and RLS, but not in patients with primary insomnia, as
compared to normal controls.
Both RLS and OSAS patients were almost five times more likely
to suffer from impaired glucose tolerance than healthy controls. In
addition, mean HbA1c values were increased in both diagnostic
groups compared to controls, and the rate of values above the
reference level in both HbA1c and fasting plasma glucose levels
indicated an increased diabetes risk in patients with OSAS (20-
fold) and RLS (9-fold), respectively. The control group was not
matched to the OSAS group with respect to gender. Indeed OSAS
patients were exclusively males. Hence, the present results should,
as far as OSAS is concerned, be replicated in a gender-mixed
patient group compared to gender-matched controls.
Impaired glucose tolerance and increased rates of diabetes have
been frequently shown in patients with OSAS [32] and might be
related, to a great extent, to obesity, which was also documented in the
present study by an increased BMI in this patient group. However,
some studies suggest that OSAS is related to type 2 diabetes
independently of obesity [33]. The idea has been put forward that
nocturnal breathing disorders comprise glucose metabolism either due
to repeated oxygen desaturation or due to disturbed sleep per se.
The present study suggests that indeed disturbed sleep itself
detoriates glucose metabolism, as non-obese RLS patients devoid
of any nocturnal breathing problem showed impaired glucose
tolerance to the same extent as OSAS patients. The positive
correlation between quantitative measures of sleep interruptions
(apnea-arousal-index in OSAS and PLMS-arousal-index in RLS)
and 2h-plasma glucose levels in the OGTT indicate repeated
arousals as a possible common mechanism of impaired glucose
tolerance in both sleep disorders. This idea is in line with the
report of Tasali [5], who induced impaired glucose tolerance in
healthy volunteers by disturbing sleep by means of acoustical
stimulation for three consecutive nights. This procedure did not
alter the total amount of sleep, suggesting a specific effect of
repeated arousals. Our results support this idea, because patients
with primary insomnia and normal glucose tolerance had similar
total sleep times compared to OSAS and RLS patients, but lacked
the repeated arousals induced by apneas or PLMS.
Repeated arousals could affect glucose metabolism by altering
sleep structure, in particular by preventing SWS. This is suggested
by a correlation between SWS and insulin sensitivity in the study
of Tasali [5]. Repeated arousals, however, could also have a direct
effect on glucose metabolism by the resulting activation of the
sympathetic nervous system. Increases in heart rate and blood
pressure are typical of both obstructive apneas and periodic leg
movements, and sympathetic nervous system activation has been
shown in both OSAS and RLS patients [34,35].
Because we restricted polysomnographic recordings to the
patient groups, the present study does not help to directly answer
the question whether sleep duration or other quantitative aspects
of night sleep, independently of arousing stimuli during sleep,
affect glucose metabolism. Indirectly, similar sleep durations of
5.5 hours in all our patient groups, including primary insomnia
patients who showed no impairment in glucose tolerance, suggests
that only more prominent sleep reduction might have a direct
negative effect on carbohydrate metabolism. One example would
be sleep curtailment to four hours of sleep for some days [4], which
impaired glucose metabolism even in healthy people.
RLS is frequently found in patients with diabetes, which so far
has mainly been explained by the fact that diabetes-induced
polyneuropathy predisposes to RLS [10]. In line with this
argument, Bosco et al. [11] found an increased incidence of small
fiber neuropathy (SFN) in RLS patients with impaired glucose
tolerance. Because we did not perform skin biopsies, we can not
judge the role of SNF in our sample. But, the present study for the
first time suggests that not only diabetes might predispose to RLS
through SNF or other mechanisms, but that in turn, RLS might be
a causative factor in the development of diabetes by compromising
sleep continuity due to repeated arousals. Moreover, the present
results further strengthen the idea that disturbed sleep in general
and chronic sleep disorders in particular might significantly
contribute to the steady increase in diabetes prevalence worldwide.
This calls for further extended investigations, because sleep
disorders are highly prevalent and might represent an important
preventive target to avoid metabolic disorders.
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